BioMarin Pharmaceutical ($BMRN) Insider Trading & Smart Money Activity
BioMarin Pharmaceutical Inc. ($BMRN) has 15 13F position changes and 1 analyst rating on file.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 0
- Net insider $ (12 mo)
- $0
- Congress trades (12 mo)
- 0
- 13F moves on file
- 15
- Analyst ratings on file
- 1
BMRN insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 0 | 0 / 0 | 11 / 3 |
| Q3 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All BMRN insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Analyst | Barclays | Reiterates to Overweight | PT $114 | Read | |||||||
| 13F | Viking Global Investors | Added | +1.03M sh | $392.23M | +4.4% | +7.4% | — | ||||
| 13F | Viking Global Investors | Added | +1.03M sh | $404.09M | +4.4% | +7.4% | — | ||||
| 13F | Lmr Partners | Added | +305.76K sh | $18.05M | +4.4% | +7.4% | — | ||||
| 13F | Lmr Partners | Added | +305.76K sh | $18.59M | +4.4% | +7.4% | — | ||||
| 13F | Caption Management | Added | +35.80K sh | $3.16M | +4.4% | +7.4% | Read | ||||
| 13F | Balyasny Asset Management L.P. | New | +1.36M sh | $75.69M | +4.4% | +7.4% | — | ||||
| 13F | Balyasny Asset Management L.P. | New | +1.36M sh | $77.98M | +4.4% | +7.4% | — | ||||
| 13F | AQR Capital Management | Added | +989.62K sh | $426.36M | +4.4% | +7.4% | — | ||||
| 13F | AQR Capital Management | Added | +989.62K sh | $439.25M | +4.4% | +7.4% | — | ||||
| 13F | Renaissance Technologies | Reduced | -300.10K sh | $57.34M | +1.6% | +4.5% | — | ||||
| 13F | Mariner | Added | +94.62K sh | $15.87M | -6.3% | +4.5% | Read | ||||
| 13F | Hudson Bay Capital Management | Added | +304.77K sh | $55.78M | -6.3% | +4.5% | — | ||||
| 13F | Primecap Management | Reduced | -355.31K sh | $788.34M | -5.5% | +6.8% | — | ||||
| 13F | Primecap Management | Reduced | -355.31K sh | $812.18M | -5.5% | +6.8% | — | ||||
| 13F | Elliott Investment Management L.P. | Sold out | -3.50M sh | — |
1W / 1M / 6M = how BMRN moved from the trade or filing date.
Institutions moving BMRN (13F)
Analyst ratings on BMRN
| Date | Firm | Action | Rating | Price target | 1W | 1M | 6M | Story |
|---|---|---|---|---|---|---|---|---|
| Barclays | Reiterates | Overweight | $111 → $114 | Read |
Frequently asked questions
Which institutions changed their BMRN positions?
Recent 13F filers moving the stock include Viking Global Investors, Lmr Partners, Balyasny Asset Management L.P., AQR Capital Management and Primecap Management.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.